The Use of Oracea and Epiduo Forte in Severe Acne Patients
Status:
Completed
Trial end date:
2019-01-04
Target enrollment:
Participant gender:
Summary
This is a single-center, open label pilot study. The study is comprised of 5 study visits;
Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD)
and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total
lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and
concomitant medications.
Phase:
Phase 4
Details
Lead Sponsor:
Derm Research, PLLC
Treatments:
Adapalene Adapalene, Benzoyl Peroxide Drug Combination Benzoyl Peroxide Doxycycline